Amniotic Membrane Treatment for Dry Eye
Amniotic membrane transplantation should be reserved for severe, refractory dry eye disease with filamentary keratitis or significant corneal epithelial defects that have failed conventional therapies, but recognize that it provides only short-term benefit and symptoms typically recur within one month of discontinuation.
When to Use Amniotic Membrane
According to the 2024 American Academy of Ophthalmology Dry Eye Preferred Practice Pattern, amniotic membrane is indicated specifically for 1:
- Severe dry eye with filamentary keratitis that is refractory to standard treatments (debridement, mucolytics, contact lenses)
- After failure of:
- Artificial tears (preserved and non-preserved)
- Anti-inflammatory agents (cyclosporine, lifitegrast)
- Topical corticosteroids
- Punctal occlusion
- Autologous serum drops
- Scleral lenses
The guideline explicitly states to use "self-retaining or sutureless amniotic membrane in refractory cases" but emphasizes "recognition of the short-term effect" 1.
Clinical Evidence for Efficacy
Recent research supports this conservative approach:
- A 2026 study of 112 patients with refractory ocular surface disease showed objective improvements in corneal and conjunctival Oxford grading, but 86.9% experienced symptom recurrence within one month after discontinuation 2
- The 2018 DREAM study (97 eyes) demonstrated significant DEWS score reduction from 3.25 to 1.44 after treatment, with placement duration of 5.4 days 3
- A 2016 study found optimal placement duration of 5 days to achieve approximately 4 months of symptom relief 4
How to Apply Amniotic Membrane
Self-retained cryopreserved amniotic membrane (e.g., PROKERA) is the preferred method:
- Placement duration: 5 days is optimal based on regression analysis 4
- Technique: Epithelial side facing upward to promote corneal re-epithelialization
- Expect: Discomfort during placement but no significant adverse events 3
- Repeat treatment: 10% of patients require repeated application for complete healing 3
Important Caveats
Do not use amniotic membrane as first-line therapy. The Taiwan consensus specifically places it at Step 4 (most severe) treatment, noting that "a combination of contact lenses with an amniotic membrane graft is better than an amniotic membrane graft alone" 5.
Manage expectations: While 88% of patients show initial improvement 3, the effect is temporary. Most patients will need to continue or resume other dry eye therapies after the membrane dissolves.
Consider patient selection carefully:
- Best results in GVHD, limbal stem cell deficiency, and Sjögren's syndrome 2
- Less effective for symptom improvement compared to objective signs 2
- 14-15% discontinuation rate due to tolerability issues 2
Treatment Algorithm Position
Place amniotic membrane after this stepwise progression:
- Mild-Moderate: Artificial tears, lid hygiene, anti-inflammatory drops (cyclosporine/lifitegrast)
- Moderate-Severe: Add topical steroids (short-term), punctal occlusion, autologous serum
- Severe: Permanent punctal cautery, scleral lenses, oral secretagogues
- Refractory Severe: Amniotic membrane for specific indications (filamentary keratitis, persistent epithelial defects)
The key distinction is that amniotic membrane is a rescue therapy for acute exacerbations in severe disease, not a maintenance treatment 1.